Stryker Co. (NYSE:SYK) Shares Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC grew its holdings in Stryker Co. (NYSE:SYK - Free Report) by 1,008.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,412 shares of the medical technology company's stock after buying an additional 23,119 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Stryker were worth $9,150,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $25,000. Rakuten Securities Inc. increased its stake in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the 4th quarter worth $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker in the fourth quarter valued at about $33,000. Finally, Activest Wealth Management acquired a new stake in Stryker during the fourth quarter worth about $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the topic of several analyst reports. Citigroup reaffirmed a "buy" rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Monday. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Evercore ISI reduced their price target on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $425.84.

Stryker Stock Down 1.1 %

Shares of SYK traded down $4.25 during midday trading on Tuesday, hitting $377.11. The company had a trading volume of 516,618 shares, compared to its average volume of 1,353,764. The company's 50-day simple moving average is $366.18 and its 200-day simple moving average is $374.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market capitalization of $143.94 billion, a P/E ratio of 48.65, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. Stryker's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.50 earnings per share. As a group, sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Monday, March 31st. Stryker's payout ratio is 45.41%.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.